FERMT2 expression in human articular chondrocytes is regulated by hypoxia-associated transcriptional programs

Abstract

Objective: Kindlin-2, encoded by FERMT2, is a focal adhesion protein essential for cartilage homeostasis and mechanotransduction. While loss of Kindlin-2 in mice induces osteoarthritis (OA)-like pathology, the upstream mechanisms regulating its expression in human cartilage remain unknown. Methods: A bioinformatics pipeline was applied to the FERMT2 promoter to predict transcriptional regulators, followed by network and enrichment analyses. Predicted candidates were validated by siRNA knockdown in the human C28/I2 chondrocyte cell line and in primary OA chondrocytes. Pathway enrichment highlighted hypoxia-related regulators, which were further tested by hypoxia mimetic treatment (IOX2) and culture under low oxygen (1% O2). Gene expression changes were quantified by qPCR, and effects on extracellular matrix (ECM) markers were assessed. Results: In silico analysis identified 21 candidate transcription factors, of which GATA1, MEF2A, and RBPJ were validated as regulators of FERMT2. Silencing of GATA1 and MEF2A reduced FERMT2 expression, whereas RBPJ knockdown increased FERMT2 in both C28/I2 cells and primary OA chondrocytes. However, RBPJ silencing also reduced ACAN and increased COL1A1, suggesting detrimental effects on ECM homeostasis. Enrichment analysis revealed a strong association between FERMT2 regulation and hypoxia pathways, supported by conserved hypoxia response elements in the promoter. Experimentally, both IOX2 and 1% O2 significantly upregulated FERMT2 expression in primary chondrocytes. Hypoxia also increased anabolic ECM genes and reduced catabolic enzymes, but these effects occurred independently of Kindlin-2. Conclusions: This study identifies hypoxia as a novel regulator of kindlin-2 expression in human cartilage, providing new insight into the upstream control of this molecule in osteoarthritis. While additional transcription factors such as GATA1, MEF2A, and RBPJ contribute to FERMT2 regulation, only hypoxia consistently enhanced FERMT2 expression without adverse ECM effects.